Management and prevention of infiltration and extravasation injury.
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D002125:Calcium Gluconate / Q000009:adverse effects; D003646:Debridement; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007269:Injections, Intra-Arterial / Q000009:adverse effects*; D007275:Injections, Intravenous / Q000009:adverse effects*; D009336:Necrosis; D009994:Osmolar Concentration; D010288:Parenteral Nutrition / Q000009:adverse effects*; D012871:Skin Diseases / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D014662:Vasoconstrictor Agents / Q000009:adverse effects
D000970:Antineoplastic Agents; D014662:Vasoconstrictor Agents; D002125:Calcium Gluconate